ANIP vs LLY: fair value comparison
ANI Pharmaceuticals, Inc. and Eli Lilly and Company · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ANIP currently sits closer to the top of our ranking by discount to fair value. ANIP carries the stronger quality grade.
| ANIP | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $72.29 | $1,179.27 |
| 12-month range | $70.16–$94.48 | $813.53–$1,280.34 |
| Rank by discount to fair value | #7 of 108 Healthcare | #9 of 108 Healthcare |
| Quality grade | A | B |
| Momentum grade | — | B |
| Leverage | Moderate | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: ANIP fair value analysis · LLY fair value analysis